A CRISPR-Cas9 platform for primary human hepatocytes enables arrayed screening and in vivo validation of HBV host factors
Ansgar F. Stenzel, Antonis Athanasiadis, Georgios Dangas, Paul Park, Anthi Maslarinou, Evgenia Moschogianni, Allan Henrique Depieri Cataneo, Catherine A. Freije, Yichen Zhou, Kenneth C Levenson, Corrine Quirk, Chenhui Zou, William M. Schneider, Adriano Aguzzi, Charles M. Rice, , Eleftherios Michailidis
The paper develops CRISPR-Cas9 delivery methods for primary human hepatocytes to enable efficient gene editing and screening of HBV host factors.
bioRxiv · Aug 18, 2026 · PreprintGenomics